Research Paper Volume 12, Issue 18 pp 18192—18208
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
Figure 4. MiR-216a-3p regulates sorafenib sensitivity in HCC cells by decreasing the protein levels of MAPK14. (A) Representative western blot shows MAPK14 protein expression in control and sorafenib-treated miR-216-3p OE, MAPK14 OE or miR-216a-3p OE plus MAPK14 OE Huh-7 cells. (B) Colony formation assay results of control and sorafenib-treated miR-216-3p OE, MAPK14 OE or miR-216a-3p OE plus MAPK14 OE Huh-7 cells. (C, D) Flow cytometry assay shows percentage apoptosis in control and sorafenib-treated miR-216-3p OE, MAPK14 OE or miR-216a-3p OE plus MAPK14 OE Huh-7 cells. (E) MTT assay results show viability of control and sorafenib-treated miR-216-3p OE, MAPK14 OE or miR-216a-3p OE plus MAPK14 OE Huh-7 cells.